When was Neoleukin Therapeutics founded?

Neoleukin Therapeutics was founded in 2003 and raised its 1st funding round 8 years after it was founded.

Where is Neoleukin Therapeutics located?

Neoleukin Therapeutics is headquartered in Seattle, United States.

How many employees does Neoleukin Therapeutics have?

As of Jul 01, 2024, the latest employee count at Neoleukin Therapeutics is 93.

Is Neoleukin Therapeutics a funded company?

Neoleukin Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Feb 10, 2011.

When was the latest funding round of Neoleukin Therapeutics?

Neoleukin Therapeutics' latest funding was a $***** Series A round on Feb 10, 2011, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.08B in funding in 2026 to date.

What is the annual revenue of Neoleukin Therapeutics?

Annual revenue of Neoleukin Therapeutics is $25M as on Dec 31, 2018.

Where does Neoleukin Therapeutics rank among its competitors?

Neoleukin Therapeutics ranks 1065th amongst 5491 active competitors, of which 1688 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Neoleukin Therapeutics?

Neoleukin Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Senti Bio secured the most recent funding round in May, 2026.

Neoleukin Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Neoleukin Therapeutics is an acquired company based in Seattle (United States), founded in 2003. It operates as a Manufacturers of therapeutic proteins to treat immunological disorders. Neoleukin Therapeutics has raised $4.72M in funding. The company has 5491 active competitors, including 1688 funded and 1176 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Neoleukin is the manufacturers of advanced computational methods to build therapeutic proteins made to treat immunological disorders, including cancer and autoimmunity. These de novo proteins with the proper intermolecular interactions to recapitulate potent IL-2 signaling while completely eliminating CD25 binding. These therapeutic proteins have improved efficacy, lower toxicity, increased stability, improved pharmacokinetic properties.

Website: neoleukin.com
Social
Email ID: *****@neoleukin.com

Key Metrics

Founded Year

2003

Location

Seattle, United States

Stage

Acquired

Total Funding

$4.72M in 1 round

Latest Funding Round

Series A, Feb 10, 2011, $*****

Investors

Sahsen Ventures & 2 more

Ranked

1065^th among 5491 active competitors

Annual Revenue

$25M as on Dec 31, 2018

Employee Count

93 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 6028 more

Exit Details

Acquired by Aquinox Pharma (Aug 06, 2019)

View Neoleukin Therapeutics' full profile

Neoleukin Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AQUINOX PHARMACEUTICALS, INC CIN: 1404644 , United States, Active		$25M (As on Dec 31, 2018)	-	-

Neoleukin Therapeutics got acquired by Aquinox Pharma on Aug 06, 2019.

Click here to take a look at Neoleukin Therapeutics's acquisition in detail

Neoleukin Therapeutics has raised a total funding of $4.72M over 1 round. Neoleukin Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Neoleukin Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 10, 2011	1100876	Series A	2950870	1214079	7043982	1231585

Access funding benchmarks and valuations. Sign up today!

View details of Neoleukin Therapeutics's funding rounds and investors

Neoleukin Therapeutics' employee count trend

Neoleukin Therapeutics has 93 employees as of Jul 24. Here is Neoleukin Therapeutics's employee count trend over the years:

Employee count trend for Neoleukin Therapeutics

Uncover Neoleukin Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neoleukin Therapeutics include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Neoleukin Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	KKR, Versant Ventures & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Arkin & 11 others	78/100
4th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
6th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Google Ventures & 15 others	72/100
10th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
1065th	Neoleukin Therapeutics 2003, Seattle (United States), Acquired	Manufacturers of therapeutic proteins to treat immunological disorders	$4.72M	Pfizer Venture Investments, Sahsen Ventures ... & 1 others	45/100